Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Optimapharm Nordic Oy
OY
Active
Y-tunnus 1982804-3
Tekniikantie 12, 02150
Espoo
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2005 · 20 years old
— employees
www.crowncro.fi
Share
Finland
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Optimapharm Nordic Oy
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
EUR millions
14M
10M
7M
3M
0M
2020: 6M
6M
2020
2021: 11M (+83% vs 2020)
11M
+83%
2021
2022: 9M (-18% vs 2021)
9M
-18%
2022
2024: 6M (-33% vs 2022)
6M
-33%
2024
2025: 3M (-50% vs 2024)
3M
-50%
2025
EBITDA
EUR millions
2M
1M
-1M
-3M
-4M
2020: -3M
-3M
2020
2021: 0M (+100% vs 2020)
0M
+100%
2021
2022: 0M
0M
2022
2024: 1M
1M
2024
2025: 0M (-100% vs 2024)
0M
-100%
2025
Income statement
EUR thousands
Item
2025
2024
2022
2021
2020
Revenue
2 563
6 486
9 148
10 698
6 454
Staff expenses
−1 536
−2 670
−3 919
−3 934
−4 416
EBITDA
−105
1 105
−89
39
−3 046
Depreciation & amort.
−3
−281
−94
−97
−150
EBIT
−108
824
−183
−57
−3 197
Net financials
262
−0
−56
−194
−253
Profit before tax
154
823
−239
−252
−3 450
Tax
−0
−0
−0
−0
−0
Net profit
154
823
−239
−252
−3 450
Balance sheet
EUR thousands
Item
2025
2024
2022
2021
2020
Total assets
1 970
2 525
3 198
3 308
2 725
Equity
231
−385
−2 324
−2 085
−3 293
Long-term debt
0
0
1 996
1 996
1 320
Short-term debt
2 202
2 910
3 527
3 398
4 698
Total debt
2 202
2 910
5 523
5 394
6 018
Financial ratios
5-year trend
EBITDA margin
−4,1 %
This company
15,8 %
Market median
This company
Market median
126% below market
2020
2025
Equity ratio
11,7 %
This company
38,2 %
Market median
This company
Market median
69% below market
2020
2025
Return on equity
66,4 %
This company
18,4 %
Market median
This company
Market median
261% above market
2020
2025
Net profit margin
6,0 %
This company
8,1 %
Market median
This company
Market median
26% below market
2020
2025
Asset turnover
1,30×
This company
1,12×
Market median
This company
Market median
16% above market
2020
2025
Debt / equity
7,52×
This company
0,62×
Market median
This company
Market median
>999% above market
2020
2025
Annual reports & filings
Annual report 2025
Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2022
Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
View
PDF
More on Optimapharm Nordic Oy
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
